Sarepta Therapeutics, Inc. (SRPT) CEO Doug Ingram on Q3 2021 Results - Earnings Call TranscriptSeeking Alpha • 11/04/21
Sarepta Therapeutics (SRPT) Reports Q3 Loss, Tops Revenue EstimatesZacks Investment Research • 11/03/21
Sarepta Therapeutics Announces Third Quarter 2021 Financial Results and Recent Corporate DevelopmentsGlobeNewsWire • 11/03/21
Sarepta Therapeutics to Announce Third Quarter 2021 Financial Results and Recent Corporate Developments on November 3, 2021GlobeNewsWire • 10/27/21
Sarepta Therapeutics Announces Pricing of $500 Million Public Offering of Common StockGlobeNewsWire • 10/14/21
Sarepta Therapeutics Announces Preliminary Financial Results for the Third Quarter Ended September 30, 2021GlobeNewsWire • 10/12/21
Sarepta Therapeutics Announces Preliminary Financial Results for the Third Quar-ter Ended September 30, 2021GlobeNewsWire • 10/12/21
Sarepta Therapeutics Announces Proposed $500,000,000 Public Offering of Common StockGlobeNewsWire • 10/12/21
Sarepta Therapeutics' SRP-9001 Shows Sustained Functional Improvements in Multiple Studies of Patients with DuchenneGlobeNewsWire • 10/11/21
Sarepta Therapeutics Opens Genetic Therapies Center of Excellence in Columbus, OhioGlobeNewsWire • 10/04/21
Sarepta Therapeutics, Inc. (SRPT) CEO Doug Ingram Presents at Cantor Fitzgerald 2021 Virtual Global Healthcare Conference (Transcript)Seeking Alpha • 09/27/21
Sarepta Therapeutics to Initiate Part B of MOMENTUM Study of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping Following Positive Interactions with FDAGlobeNewsWire • 09/27/21
Sarepta Therapeutics to Showcase Data from its Gene Therapy and RNA Platforms at World Muscle Society 2021 Virtual CongressGlobeNewsWire • 09/14/21
Sarepta Therapeutics, Inc. (SRPT) CEO Doug Ingram Presents at Morgan Stanley 19th Annual Global Healthcare Conference (Transcript)Seeking Alpha • 09/13/21
How Does Sarepta's Stock Performance In The Current Crisis Compare With That In 2008?Forbes • 09/07/21